Some cancer treatments already work by teaching a patient’s own immune cells to hunt tumours down — but every single dose has to be built by hand, in a specialised facility, over several weeks, for a sum close to 300 000 euros. A team in Utrecht asked a different question: instead of shipping the cells to the factory, why not send the factory to the cells? Their answer is one injection of a nanoparticle — and the habit of mind behind that kind of reversal is exactly what the test at the end of this article is about.
CAR-T therapy is not a pill and not a course of chemotherapy. It is a living drug made out of the patient’s own white blood cells. Doctors collect T-cells from the person being treated, equip them with a gene for a chimeric antigen receptor, and give the cells back. The receptor works a little like a pair of glasses: it lets the immune system see a tumour it had previously walked straight past.
The results can be spectacular, and so can the invoice. A single course of conventional CAR-T treatment can reach 300 000 euros. That price is not a mark-up on a chemical — it is the cost of manufacturing one unique batch of cells for one single patient, under clinical-grade conditions, with nothing left over for anybody else.
The delay is built into the procedure itself. Every conventional CAR-T dose goes through the same chain of steps:
"Conventional CAR-T works by taking a patient’s T-cells out, engineering them with viruses, and growing them over several weeks in specialised facilities before returning them to the body," explains Raymond Schiffelers, vice-president of preclinical research and development at NanoCell Therapeutics and lecturer in nanomedicine at Utrecht University. Each of those stages needs people, equipment and time — and for somebody with an aggressive leukaemia, time is the scarcest ingredient of all.
The NANO-ENGINE project, coordinated by Utrecht University in the Netherlands and backed by the European Innovation Council, did not set out to make that chain run faster. It set out to delete most of it.
"We wanted to establish a proof of concept for a first-in-class, DNA-based, non-viral platform capable of reprogramming T-cells directly in the body using a single injection of an off-the-shelf targeted nanoparticle," says Schiffelers. Off-the-shelf is the phrase that carries the weight here: something produced in advance, identical for everyone, waiting in a fridge instead of being assembled to order. The project ran on a total budget of 2 988 377.95 euros, of which 2 988 377.70 euros came from EU funding.
The carrier will sound familiar to anyone who followed the pandemic — it is a lipid nanoparticle, a close relative of the ones used in COVID-19 vaccines. What travels inside is the new part. Instead of mRNA there is minicircle DNA carrying the instructions for the CAR receptor, together with an enzyme with an unlikely name: the Sleeping Beauty transposase.
That enzyme does the job a virus would normally be hired for. It stitches the new gene into the cell’s own chromosomes for good, so the receptor does not fade after a few days the way an mRNA-encoded protein would. The outside of the particle carries binders that recognise markers on T-cells, so the cargo is delivered to the right cells rather than scattered across the body.
"We showed that just a single intravenous dose of this targeted nanoparticle generates functional CAR-T cells in vivo, controls tumour growth and significantly extends survival in a leukaemia model – all at doses well below those used with an mRNA approach," reports Schiffelers. The findings were published in the Journal for ImmunoTherapy of Cancer.
In plain terms: one drip, cells reprogrammed inside the body, a tumour held back, longer survival in a leukaemia model — and less material needed than an mRNA-based route would demand.
None of this is available in a clinic. What exists is a proof of concept in a laboratory model, which is a long way from something a patient can be prescribed. Anyone reading a headline about cancer being solved should keep that distance firmly in view.
The platform is modular, though, and that is where its appeal lies. Change the genetic cargo, change the binders on the surface, and the same delivery system could in principle be pointed somewhere else. The team is already looking towards autoimmune diseases and solid tumours, which are considerably harder to reach than blood cancers. The work continues in the NANOCAR project and under an ERC Advanced Grant, with clinical use as the stated destination.
CAR-T therapy works, but it is slow and extraordinarily expensive because every dose is manufactured individually outside the body. NANO-ENGINE removed that stage instead of optimising it, using a targeted lipid nanoparticle that reprograms T-cells in vivo after one injection. It is an early-stage result — and a neat illustration of what happens when chemistry, molecular biology, medicine and materials engineering are made to sit at the same table.
5 questions · one minute · nothing is saved
EN 
CS
DE
ES
FR
HU
IT
PL
PT
РУ
SK
TR
УК
AR
中文
